% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Dronse:138922,
      author       = {Dronse, Julian and Fliessbach, Klaus and Bischof, Gérard N
                      and von Reutern, Boris and Faber, Jennifer and Hammes,
                      Jochen and Kuhnert, Georg and Neumaier, Bernd and Onur,
                      Oezguer A and Kukolja, Juraj and Eimeren, Thilo and Jessen,
                      Frank and Fink, Gereon R and Klockgether, Thomas and
                      Drzezga, Alexander},
      title        = {{I}n vivo {P}atterns of {T}au {P}athology, {A}myloid-β
                      {B}urden, and {N}euronal {D}ysfunction in {C}linical
                      {V}ariants of {A}lzheimer's {D}isease.},
      journal      = {Journal of Alzheimer's disease},
      volume       = {55},
      number       = {2},
      issn         = {1387-2877},
      address      = {Amsterdam},
      publisher    = {IOS Press},
      reportid     = {DZNE-2020-05244},
      pages        = {465-471},
      year         = {2017},
      abstract     = {The clinical heterogeneity of Alzheimer's disease is not
                      reflected in the rather diffuse cortical deposition of
                      amyloid-β. We assessed the relationship between clinical
                      symptoms, in vivo tau pathology, amyloid distribution, and
                      hypometabolism in variants of Alzheimer's disease using
                      novel multimodal PET imaging techniques. Tau pathology was
                      primarily observed in brain regions related to clinical
                      symptoms and overlapped with areas of hypometabolism. In
                      contrast, amyloid-β deposition was diffusely distributed
                      over the entire cortex. Tau PET imaging may thus serve as a
                      valuable biomarker for the localization of neuronal injury
                      in vivo and may help to validate atypical subtypes of
                      Alzheimer's disease.},
      keywords     = {Alzheimer Disease: complications / Alzheimer Disease:
                      diagnostic imaging / Alzheimer Disease: pathology / Amyloid
                      beta-Peptides: metabolism / Atrophy: etiology / Brain:
                      diagnostic imaging / Brain: metabolism / Brain: pathology /
                      Carbolines: metabolism / Cognition Disorders: diagnostic
                      imaging / Cognition Disorders: etiology / Corticomedial
                      Nuclear Complex: pathology / Executive Function / Female /
                      Fluorodeoxyglucose F18: metabolism / Humans / Language
                      Disorders: etiology / Male / Neuropsychological Tests /
                      Positron-Emission Tomography / tau Proteins: metabolism /
                      Amyloid beta-Peptides (NLM Chemicals) / Carbolines (NLM
                      Chemicals) / tau Proteins (NLM Chemicals) /
                      Fluorodeoxyglucose F18 (NLM Chemicals) /
                      7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (NLM
                      Chemicals)},
      cin          = {AG Jessen / AG Boecker},
      ddc          = {610},
      cid          = {I:(DE-2719)1011102 / I:(DE-2719)1011202},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27802224},
      doi          = {10.3233/JAD-160316},
      url          = {https://pub.dzne.de/record/138922},
}